KRAS Inhibitors Market Size in 7MM Set to Surge from USD 526 Million in 2025 to USD 7,847 Million by 2034

• The KRAS Inhibitors market in the 7MM was valued at approximately USD 526 million in 2025 and is projected to reach USD 7,847 million by 2034, growing at a CAGR of 35% over the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the KRAS inhibitors landscape.
• Among the 7MM, the United States captured the highest KRAS inhibitors market size in 2024, accounting for nearly 70% of the total market share. Within the EU4 and the UK, Germany had the highest KRAS inhibitors market size in 2024, while Spain had the lowest. The KRAS inhibitors market size in Japan was approximately 6% of the total 7MM market in 2024.
• The total KRAS-mutated cases in the 7MM comprised more than ~509,700 cases in 2024 and are projected to increase during the forecast period. Among the selected cancer types, the most KRAS mutant cases are found in CRC, followed by pancreatic cancer, NSCLC, and LGSOC. In the United States, there were about ~66,000 cases of KRAS mutant colorectal cancer in 2024. The United States also had the highest number of KRAS mutation cases in NSCLC among the 7MM, with approximately 46% of all such cases reported there.
• Among the approved therapies in the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenue generated during the study period (2020–2034). Overall, AVMAPKI + FAKZYNJA is expected to capture more KRAS inhibitors market share than KRAZATI and LUMAKRAS throughout the study period, while among emerging therapies, Onvansertib is expected to generate the highest revenue by 2034.

DelveInsight's report "KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" provides a comprehensive analysis of the KRAS inhibitors landscape. The report delivers an in-depth understanding of KRAS inhibitors, including historical and forecasted epidemiology, helping stakeholders understand the incident cases, KRAS-mutated cases, and KRAS variant cases across key regions.

Additionally, it examines KRAS inhibitors market dynamics, offering a thorough assessment of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, and also covers KRAS inhibitor treatment algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

To Know in detail about the KRAS inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; KRAS Inhibitors Market Forecast

Some of the key facts of the KRAS Inhibitors Market Report:

• Key KRAS Inhibitors Companies: Amgen, Verastem Oncology, Revolution Medicines, Roche, Eli Lilly and Company, and others
• Key KRAS Inhibitors Therapies: LUMAKRAS, KRAZATI, AVMAPKI + FAKZYNJA Co-Pack, Divarasib, D3S-001, BDTX-4933, and others
• 2025 KRAS Inhibitors Market Size: USD 526 million; 2034 Projected KRAS Inhibitors Market Size: USD 7,847 million
• KRAS Inhibitors Growth Rate (2025–2034): 35% CAGR
• Largest KRAS Inhibitors Market: United States
• The current landscape of KRAS-targeted drug development is heavily focused on the G12C mutation, with the majority of approved therapies and investigational agents specifically designed for this variant, while many KRAS subtypes still have no treatment options.

KRAS Inhibitors Overview

KRAS belongs to a group of small GTP-binding proteins known as the RAS superfamily or RAS-like GTPases. RAS functions as a signal transducer, important for regulating cell proliferation, differentiation, and survival in normal and malignant cells. The RAS-RAF-MEK-ERK pathway is one of the best-characterized signal transduction pathways, and its aberrancies are commonly implicated in the development of multiple cancer types. KRAS is the most frequently mutated of the three RAS genes, followed by NRAS and HRAS, and KRAS mutations are commonly associated with pancreatic, colorectal, lung adenocarcinoma, ovarian, and other cancers. Historically, KRAS mutations have been challenging to target; however, recent research has led to promising strategies, although approved treatments remain limited to NSCLC only. Generally, treatment for KRAS-mutated cancers includes surgery, radiation therapy, chemotherapy, targeted therapies, immunotherapy, and others.

Get a Free sample for the KRAS Inhibitors Market Forecast, Size & Share Analysis Report: KRAS Inhibitors Market Forecast

Key Trends in the KRAS Inhibitors Market:

• Large, addressable patient population across solid tumors: KRAS mutations span NSCLC, CRC, pancreatic cancer, ovarian cancer, and others, creating a broad base of patients who may benefit from targeted therapies.
• Expanding opportunities in the pan-KRAS space: Many KRAS subtypes have no treatment options, and pan-KRAS-targeting medicines can address a wider patient base. Cardiff Oncology (onvansertib), Immuneering Corporation (IMM-1-104), Jacobio Pharma (JAB-23E73), and Eli Lilly and Company (LY4066434) are among those developing pan-KRAS candidates.
• Growing interest in the KRAS G12D mutation: Companies such as Tyligand Pharmaceuticals (Suzhou), Verastem Oncology and GenFleet Therapeutics, AstraZeneca, PAQ Therapeutics, and Astellas Pharma are developing therapies targeting KRAS G12D, with additional companies rapidly emerging.
• Differentiated approaches beyond KRAS "off" inhibitors: Revolution Medicines focuses on targeting the active, or "on," states of KRAS proteins, which the company believes may offer a therapeutic advantage over KRAS "off" inhibitors such as LUMAKRAS and KRAZATI.
• Combination strategies and expansion beyond NSCLC: Pairing KRAS inhibitors with chemotherapy, immune checkpoint inhibitors, or pan-KRAS agents is under active investigation, and key players are expanding research into other cancer types.

KRAS Inhibitors Epidemiology

As the KRAS inhibitors market is derived using a patient-based model, the epidemiology chapter of the report provides historical as well as forecasted epidemiology segmented by total incident cases of NSCLC, CRC, pancreatic cancer, and LGSOC, total KRAS incident cases, and total KRAS variant cases in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

Key findings from the KRAS inhibitors epidemiological analyses and forecast:

• The total KRAS-mutated cases in the 7MM comprised more than ~509,700 cases in 2024 and are projected to increase during the forecast period.
• Among the selected cancer types, the most KRAS mutant cases are found in CRC, followed by pancreatic cancer, NSCLC, and LGSOC.
• In the United States, there were about ~66,000 cases of KRAS mutant colorectal cancer in 2024.
• The most frequent KRAS variant observed in NSCLC is G12C, while the most common KRAS variation in CRC, pancreatic cancer, and LGSOC is G12D.
• In the United States, KRAS G12C is present in ~37% of NSCLC cases, and the highest rates of KRAS G12D, i.e., ~42%, ~30%, and ~42%, were found in pancreatic cancer, CRC, and LGSOC, respectively.
• In Japan, the contribution of KRAS mutations is lower compared to Western countries like the United States and Europe.

KRAS Inhibitors Epidemiology Segmentation:

The KRAS inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases in Selected Indications
• Total KRAS Mutated Cases of Selected Indications
• Total KRAS Variant Cases of Selected Indications

Download the report to understand which factors are driving KRAS inhibitors epidemiology trends @ KRAS Inhibitors Epidemiology Forecast

Recent Developments in the KRAS Inhibitors Treatment Landscape:

• In August 2026, The Lustgarten Foundation and Break Through Cancer launched a new clinical trial evaluating a novel KRAS-targeted immunotherapy strategy. The study focuses on evaluating target-driven combination therapies to improve clinical outcomes for patients suffering from pancreatic ductal adenocarcinoma.
• In August 2026, Eli Lilly and Company earned U.S. FDA Breakthrough Therapy Designation for olomorasib in treating previously treated KRAS G12C-mutant advanced pancreatic cancer. The designation accelerates the development and regulatory evaluation of this targeted therapeutic for patients with limited remaining treatment options.
• In May 2025, Verastem Oncology announced that the US FDA approved AVMAPKI + FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent LGSOC who received prior systemic therapy. It is the first and only FDA-approved medicine for this disease, approved under accelerated approval based on the tumor response rate and DoR.
• In April 2025, BMS announced anticipation of Phase III trial data readouts for KRYSTAL-10 by 2026 for 2L CRC, KRYSTAL-7 trial results in 2028 for 1L NSCLC PD-L1=50%, and KRYSTAL-4 trial results in 2029 for 1L NSCLC.
• In March 2025, Verastem Oncology announced plans to launch avutometinib in the first half of 2025 to maximize market opportunity in KRAS mutant recurrent LGSOC. The company plans to submit for NCCN Guideline inclusion upon FDA approval, which may enable patients with KRAS wild-type LGSOC to access therapy.
• According to BMS's Q1 2025 presentations, KRAZATI (KRYSTAL-17) early-stage data for 1L NSCLC (TPS <50%) are expected in 2025.
• In January 2025, Elicio Therapeutics announced that, based on the feedback from the FDA in the End of Phase I Type B meeting, the company anticipates submitting a BLA contingent upon the results of a planned Phase III trial.

KRAS Inhibitors Drugs and Pipeline Development Activities

The drug chapter segment of the KRAS inhibitors report encloses a detailed analysis of marketed drugs such as LUMAKRAS/LUMYKRAS, KRAZATI, AVMAPKI + FAKZYNJA Co-Pack, and late-stage (Phase III and Phase II) pipeline drugs including divarasib, daraxonrasib, olomorasib, MK-1084, and others. It also helps understand the KRAS inhibitors clinical trial details, pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed KRAS inhibitors:

• LUMAKRAS/LUMYKRAS (sotorasib): Amgen. The drug received accelerated approval from the FDA in May 2021 for KRAS G12C-mutated locally advanced or metastatic NSCLC, was approved in Japan in January 2022, and received US approval for KRAS G12C-mutated CRC in January 2025. Amgen stated that LUMAKRAS has multiple patents in the US and Europe, ensuring market exclusivity until 2040.
• KRAZATI (adagrasib): Bristol Myers Squibb (Mirati Therapeutics). KRAZATI received FDA approval and launched commercially in the US in December 2022, and the EC granted conditional marketing authorization in January 2024. It has also been incorporated into NCCN Guidelines for CNS-metastatic NSCLC.
• AVMAPKI + FAKZYNJA Co-Pack (avutometinib + defactinib): Verastem Oncology. The first FDA-approved therapy for KRAS-mutated recurrent LGSOC, approved in May 2025.

Emerging KRAS inhibitors:

• Olomorasib (LY3537982): Eli Lilly and Company. A second-generation KRAS G12C inhibitor currently in Phase III, with three ongoing clinical trials in KRAS G12C-mutant advanced NSCLC and other solid tumors.
• MK-1084: Merck, Taiho, and Astex Pharmaceuticals. An investigational oral, selective KRAS G12C inhibitor being developed in combination with KEYTRUDA, with the anticipated US expiration year of 2040.
• Divarasib (Roche/Chugai/Genentech) and Daraxonrasib (Revolution Medicines) are also in Phase III development.

KRAS Inhibitors Therapies and Key Companies

• LUMAKRAS/LUMYKRAS (sotorasib): Amgen
• KRAZATI (adagrasib): Bristol Myers Squibb (Mirati Therapeutics)
• AVMAPKI + FAKZYNJA Co-Pack: Verastem Oncology
• Divarasib: Roche/Chugai/Genentech
• Daraxonrasib: Revolution Medicines
• Olomorasib: Eli Lilly and Company
• MK-1084: Merck, Taiho, and Astex Pharmaceuticals
• Onvansertib: Cardiff Oncology
• ELI-002: Elicio Therapeutics
• HRS-4642: Jiangsu Hengrui Pharmaceuticals
• DUPERT (Fulzerasib/GFH925): Genfleet Therapeutics and Innovent
• JAB-23E73: Jacobio Pharma
• TSN1611: Tyligand Pharmaceuticals (Suzhou)
• SIL204: Silexion Therapeutics and Catalent
• ASP3082: Astellas Pharma
• INCB186748: Incyte
• PF-07985045 and PF-07934040: Pfizer
• BAY3498264: Bayer
• KQB365: Kumquat Biosciences
• QTX3544: Quanta Therapeutics
• D3S-001: D3 Bio

KRAS Inhibitors Market Drivers

• Large, Addressable Patient Population Across Solid Tumors: KRAS mutations are commonly associated with pancreatic, colorectal, lung adenocarcinomas, ovarian, and other cancers, creating a wide patient base.
• Promise of Combination Approaches in KRAS Therapies: Combining KRAS-targeted therapies with immunotherapies or traditional chemotherapy holds promise for improving treatment outcomes and creates additional market opportunities.
• Expanding Opportunities in the Pan-KRAS Space: Pan-KRAS candidates are expected to have tremendous market potential due to the broad target patient population they can address.
• Advancing Treatment Across Mutation Subtypes and Tumor Types: Candidates such as divarasib, daraxonrasib, and olomorasib aim to expand the therapeutic scope of KRAS-targeted treatment across mutation subtypes and tumor types.

KRAS Inhibitors Market Barriers

• Resistance Mechanisms: Primary and acquired resistance to KRAS G12C inhibitors remains a key hurdle.
• Tumor Heterogeneity: KRAS-driven cancers remain challenging due to tumor heterogeneity and resistance mechanisms.
• Limited Treatment Scope: Approved treatments for KRAS-mutated cancers have largely been limited to NSCLC, and many KRAS subtypes have no treatment options.
• Pricing and Reimbursement Pressure: LUMAKRAS witnessed a decrease in sales, primarily due to a price adjustment implemented as part of a reimbursement agreement in Germany.
• Focus on a Single Variant: The current drug development landscape is heavily focused on the G12C mutation, leaving a need for effective therapies targeting other KRAS variants.

Scope of the KRAS Inhibitors Market Report

• Study Period: 2020–2034
• Forecast Period: 2025–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key KRAS Inhibitors Companies: Amgen, Verastem Oncology, Revolution Medicines, Roche, Eli Lilly and Company, and others
• Key KRAS Inhibitors Therapies: LUMAKRAS, KRAZATI, AVMAPKI + FAKZYNJA Co-Pack, Divarasib, D3S-001, BDTX-4933, and others
• KRAS Inhibitors Market Segmentation: By Region and By Therapies
• KRAS Inhibitors Market Analysis: KOL views, SWOT analysis, Reimbursement, Conjoint analysis, Unmet needs

To know more about KRAS inhibitors companies working in the treatment market, visit @ KRAS Inhibitors Clinical Trials and Therapeutic Assessment